Immatics (IMTX) to Release Quarterly Earnings on Thursday

Immatics (NASDAQ:IMTX) will likely be issuing its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 5, 2026 at 7:00 AM ET.

Immatics (NASDAQ:IMTX) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.14. The firm had revenue of $23.00 million during the quarter, compared to analysts’ expectations of $12.18 million. Immatics had a negative net margin of 411.90% and a negative return on equity of 41.81%. On average, analysts expect Immatics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immatics Stock Up 0.8%

Shares of NASDAQ:IMTX opened at $9.51 on Tuesday. Immatics has a 52 week low of $3.30 and a 52 week high of $12.41. The company has a 50-day moving average price of $9.86 and a 200 day moving average price of $9.55. The company has a market cap of $1.28 billion, a P/E ratio of -5.17 and a beta of 1.34.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Tudor Investment Corp ET AL acquired a new stake in shares of Immatics during the 4th quarter worth about $575,000. Jump Financial LLC acquired a new position in shares of Immatics in the fourth quarter valued at approximately $534,000. Vanguard Personalized Indexing Management LLC raised its position in shares of Immatics by 3.7% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 49,374 shares of the company’s stock valued at $518,000 after buying an additional 1,739 shares during the last quarter. Barclays PLC lifted its stake in shares of Immatics by 11.4% during the fourth quarter. Barclays PLC now owns 28,185 shares of the company’s stock valued at $296,000 after buying an additional 2,874 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Immatics by 18.2% during the fourth quarter. The Manufacturers Life Insurance Company now owns 55,300 shares of the company’s stock valued at $557,000 after buying an additional 8,500 shares during the period. Institutional investors and hedge funds own 64.41% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on IMTX. Chardan Capital reissued a “buy” rating and set a $25.00 target price on shares of Immatics in a research note on Monday, November 24th. Mizuho set a $25.00 price target on Immatics in a research note on Thursday, February 19th. Wall Street Zen raised Immatics from a “sell” rating to a “hold” rating in a report on Monday, March 9th. Leerink Partners reiterated an “outperform” rating and issued a $17.00 price objective on shares of Immatics in a research report on Thursday, December 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Immatics in a report on Thursday, January 22nd. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Immatics presently has a consensus rating of “Moderate Buy” and an average price target of $19.00.

Immatics Company Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.